Antiepileptika og medfødte misdannelser

Tidsskrift for den Norske Laegeforening

Volumn 134, Issue 12-13, 2014, Pages 1239-1242

  Nakken, Karl O ^a   Lillestølen, Kari Mette ^a   Brodtkorb, Eylert ^b   Svendsen, Torleiv ^a,c   Haggag, Kathrine Johannessen ^d   Taubøll, Erik ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c Sykehuset Innlandet Trust   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; EPILEPSY; FEMALE; HUMAN; INFANT; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTICONVULSANTS; COHORT STUDIES; EPILEPSY; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84903750058     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.13.1349     Document Type: Article

References (26)

1. Meador K, Reynolds MW, Crean S et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008; 81: 1-13.
2. Samrén EB, van Duijn CM, Christiaens GC et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739-46.
3. Kaneko S, Battino D, Andermann E et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33: 145-58.
4. Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-8.
5. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006; 66: 354-60.
6. Nakken KO, Lillestølen KM, Taubøll E et al. Epilepsi og svangerskap-medikamentbruk, anfallskontroll og komplikasjoner. Tidsskr Nor Lægeforen 2006; 126: 2507-10.
7. Tomson T, Battino D, Bonizzoni E et al. Dosedependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10: 609-17.
8. EUROCAT. www.eurocat-network.eu/(21.3.2014).
9. Årstabeller for Medisinsk fødselsregister 2011. Fødsler i Norge. Oslo: Divisjon for epidemiologi, Folkehelseinstituttet, 2013.
10. Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-8.
11. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012; 11: 803-13.
12. Hernández-Díaz S, Smith CR, Shen A et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78: 1692-9.
13. Campbell E, Kennedy F, Russell A et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014. E-publisert 3.2.
14. Vajda FJ, Graham J, Roten A et al. Teratogenicity of the newer antiepileptic drugs-the Australian experience. J Clin Neurosci 2012; 19: 57-9.
15. Vajda FJ, Graham J, Hitchcock AA et al. Foetal malformations after exposure to antiepileptic drugs in utero assessed at birth and 12 months later: observations from the Australian pregnancy register. Acta Neurol Scand 2011; 124: 9-12.
16. Vajda FJ, Hitchcock AA, Graham J et al. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51: 805-10.
17. Reimers A, Brodtkorb E. Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev Neurother 2012; 12: 707-17.
18. Reisinger TL, Newman M, Loring DW et al. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav 2013; 29: 13-8.
19. Røste LS. Retningslinjer for behandling av kvinner med epilepsi. Konsensusrapport. Oslo: Den norske legeforening, 2011.
20. Harden CL, Hopp J, Ting TY et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50: 1229-36.
21. Harden CL, Meador KJ, Pennell PB et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50: 1237-46.
22. Luef G. Female issues in epilepsy: a critical review. Epilepsy Behav 2009; 15: 78-82.
23. Verrotti A, D'Egidio C, Mohn A et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011; 52: 199-211.
24. Kariuki JG, Joshi MD, Adam AM et al. Fertility rate of epileptic women at Kenyatta National Hospital. East Afr Med J 2008; 85: 341-6.
25. Thomas SV, Sindhu K, Ajaykumar B et al. Maternal and obstetric outcome of women with epilepsy. Seizure 2009; 18: 163-6.
26. Yerby MS, Kaplan P, Tran T. Risks and management of pregnancy in women with epilepsy. Cleve Clin J Med 2004; 71 (suppl 2): S25-37.